Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.
In: Human Psychopharmacology: Clinical & Experimental, Jg. 28 (2013-05-01), Heft 3, S. 205-214
Online
academicJournal
Zugriff:
Objective The pharmacokinetics of olanzapine and response to treatment could be affected by polymorphisms in genes coding for drug-metabolizing enzymes, transporters, or receptors. The aim of this study was to identify genetic markers predictive of pharmacokinetics, pharmacodynamics, and adverse effects of olanzapine. Methods Sixty-three healthy volunteers receiving a single 5-mg oral dose of olanzapine were genotyped for 39 genetic variants that could be related to the response to olanzapine. All genetic variants were analyzed by PharmaChip, but DRD2 Taq1A polymorphism was determined by real-time polymerase chain reaction. Olanzapine was measured using high-performance liquid chromatography combined with tandem mass spectrometry. The relationship of gender and polymorphisms with olanzapine pharmacokinetics, the change in prolactin levels, and the incidence of adverse effects were evaluated by multiple regression analysis. Results The pharmacokinetics of olanzapine was influenced by polymorphisms in CYP3A5, GSTM3, and GRIN2B. Prolactin levels were affected by gender and polymorphisms in DRD2 and 5- HTR2A. Polymorphisms in CYP2C9, TPMT, UGT1A1, MDR1, and 5- HTR2A were related to some adverse effects of olanzapine. Conclusions Several polymorphisms can explain differences in the pharmacokinetics, pharmacodynamics, and safety of olanzapine in healthy subjects. Whether these genetic factors influence the risk of therapeutic failure or tolerability in patients remains to be established. Copyright © 2013 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.
|
---|---|
Autor/in / Beteiligte Person: | Cabaleiro, Teresa ; López‐Rodríguez, Rosario ; Ochoa, Dolores ; Román, Manuel ; Novalbos, Jesús ; Abad‐Santos, Francisco |
Link: | |
Zeitschrift: | Human Psychopharmacology: Clinical & Experimental, Jg. 28 (2013-05-01), Heft 3, S. 205-214 |
Veröffentlichung: | 2013 |
Medientyp: | academicJournal |
ISSN: | 0885-6222 (print) |
DOI: | 10.1002/hup.2308 |
Schlagwort: |
|
Sonstiges: |
|